REFERENCES:
1. Al-Khatib Sana M., Stevenson William G., Ackerman Michael J., Bryant William J., Callans David J., Curtis Anne B., et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2018 Sep 25;138(13):e272–391.
2. Naksuk N, Saab A, Li J-M, Florea V, Akkaya M, Anand IS, et al. Incidence of appropriate shock in implantable cardioverter-defibrillator patients with improved ejection fraction. J Card Fail. 2013 Jun;19(6):426–30.
3. Kini V, Soufi MK, Deo R, Epstein AE, Bala R, Riley M, et al. Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement. J Am Coll Cardiol. 2014 Jun 10;63(22):2388–94.
4. Zhang Y, Guallar E, Blasco-Colmenares E, Butcher B, Norgard S, Nauffal V, et al. Changes in follow-up left ventricular ejection fraction associated with outcomes in primary prevention ICD and CRT-D recipients. J Am Coll Cardiol. 2015 Aug 4;66(5):524–31.
5. Vakil K, Florea V, Koene R, Kealhofer JV, Anand I, Adabag S. Effect of Coronary Artery Bypass Grafting on Left Ventricular Ejection Fraction in Men Eligible for Implantable Cardioverter-Defibrillator. Am J Cardiol. 2016 Mar 15;117(6):957–60.
6. Madhavan M, Waks JW, Friedman PA, Kramer DB, Buxton AE, Noseworthy PA, et al. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death. Circ Arrhythm Electrophysiol. 2016 Mar;9(3):e003283.
7. Adabag S, Patton KK, Buxton AE, Rector TS, Ensrud KE, Vakil K, et al. Association of implantable cardioverter defibrillators with survival in patients with and without improved ejection fraction. JAMA Cardiol. 2017 Jul;2(7):767–74.
8. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan 20;352(3):225–37.
9. Bardy G, Lee K, Mark D, Poole J, Fishbein D. The Sudden Cardiac Death–Heart Failure Trial (SCD-HeFT). In: In: Woosley RL, Singh SN, editors Arrhythmia Treatment and Therapy: Evaluation of Clinical Trial Evidence. New York: Marcel Dekker; 2000. p. 323–42.
10. BioLINCC - Biologic Specimen and Data Repository Information Coordinating Center [Internet]. [cited 2020 Mar 8]. Available from: https://biolincc.nhlbi.nih.gov/home/
11. Ruwald Martin H., Solomon Scott D., Foster Elyse, Kutyifa Valentina, Ruwald Anne-Christine, Sherazi Saadia, et al. Left Ventricular Ejection Fraction Normalization in Cardiac Resynchronization Therapy and Risk of Ventricular Arrhythmias and Clinical Outcomes. Circulation. 2014 Dec 1;130(25):2278–86.
12. Lupón J, Gavidia-Bovadilla G, Ferrer E, de Antonio M, Perera-Lluna A, López-Ayerbe J, et al. Dynamic trajectories of left ventricular ejection fraction in heart failure. J Am Coll Cardiol. 2018 Aug;72(6):591–601.
13. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013 Mar 6;309(9):896–908.
14. Anantha Narayanan M, Vakil K, Reddy YN, Baskaran J, Deshmukh A, Benditt DG, et al. Efficacy of Implantable Cardioverter-Defibrillator Therapy in Patients With Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. JACC Clin Electrophysiol. 2017;3(9):962–70.
15. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med. 2016 29;375(13):1221–30.
16. Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet Lond Engl. 2019 Jan 5;393(10166):61–73.
17. Cioffi G, Stefenelli C, Tarantini L, Opasich C. Chronic left ventricular failure in the community: prevalence, prognosis, and predictors of the complete clinical recovery with return of cardiac size and function to normal in patients undergoing optimal therapy. J Card Fail. 2004 Jun;10(3):250–7.
18. Adabag S, Smith LG, Anand IS, Berger AK, Luepker RV. Sudden cardiac death in heart failure patients with preserved ejection fraction. J Card Fail. 2012 Oct;18(10):749–54.
19. Adabag S, Langsetmo L. Sudden cardiac death risk prediction in heart failure with preserved ejection fraction. Heart Rhythm. 2020 Mar;17(3):358–64.
20. Adabag S, Rector TS, Anand IS, McMurray JJ, Zile M, Komajda M, et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2014 Nov;16(11):1175–82.
21. Pellikka PA, She L, Holly TA, Lin G, Varadarajan P, Pai RG, et al. Variability in Ejection Fraction Measured By Echocardiography, Gated Single-Photon Emission Computed Tomography, and Cardiac Magnetic Resonance in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. JAMA Netw Open. 2018 03;1(4):e181456.